Previous 10 | Next 10 |
Anavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Conference Call February 7, 2023, 08:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants So...
Anavex Life Sciences press release ( NASDAQ: AVXL ): Q1 GAAP EPS of -$0.17 beats by $0.02 . Cash and cash equivalents of $143.6M. Shares -5.4% PM. CEO comment: “We look forward to presenting the complete dataset of the study as well as other long-term study ...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiat...
Anavex Life Sciences ( NASDAQ: AVXL ) is scheduled to announce Q1 earnings results on Tuesday, February 7th, before market open. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions ...
The shares of Anavex Life Sciences ( NASDAQ: AVXL ) gained Thursday pre-market after the clinical-stage biotech announced better than expected patient enrollment in its EXCELLENCE Phase 2/3 study for Rett syndrome candidate ANAVEX®2-73 (blarcamesine). With its enrollment at 92, e...
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
Summary FDA grants emergency approval of Biogen/Eisai's Leqembi (previously Lecanemab), based solely on Phase 2 trial results; Phase 3 results to be considered for final approval. Anavex Life Sciences produces the alternative Alzheimer's drug Blarcamesine, which appears more effective, ...
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
A stock that trades at $15 or less isn't necessarily a bargain. Often, a stock trading that low is risky and anything but a bargain. However, biotech stocks Novavax (NASDAQ: NVAX) , MannKind (NASDAQ: MNKD) , and Anavex Life Sciences (NASDAQ: AVXL) all trade at $15 or l...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...